ArticleClinical epigenetics2025
Multi-locus methylation analyses reveal GNAS methylation defects in three patients with the Beckwith-Wiedemann syndrome phenotype and no molecular defects in the 11p15.5 imprinted region.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe infantile obesity with a maternalClinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBeckwith-Wiedemann syndrome (BWS) is a congenital imprinting disorder (ID) caused by molecular defects in the 11p15.5 imprinted region, such as hypomethylation of the KCNQ1OT1:TSS-differentially methylated region (KCNQ1OT1-DMR) and hypermethylation of the H19/IGF2:IG-DMR, and maternal CDKN1C pathogenic variants, with various clinical characteristics, including overgrowth and macroglossia. Recently, the concept of Beckwith-Wiedemann spectrum (BWSp) and a clinical scoring system for BWS have been proposed, and cases with four or more points are diagnosed with classic BWS, and 20% of cases with BWS have no molecular defects in the 11p15.5 imprinted region. Pseudohypoparathyroidism type 1B (PHP1B, alias inactivating parathyroid hormone (PTH)/PTH-related protein signaling disorder 3) has characteristics of hormone resistance, particularly PTH, caused by methylation defects in DMRs at the GNAS locus (GNAS-DMRs). Some cases with PHP1B show postnatal overgrowth, which overlaps the BWS-phenotype. However, no studies have conducted a multi-locus methylation analysis for the ID-responsible DMRs other than the DMRs in 11p15.5 in cases with the BWS-phenotype and without molecular defects in the 11p15.5 imprinted region.
resultsWe conducted methylation analysis using pyrosequencing in 77 patients showing the BWS-phenotype without molecular defects in the 11p15.5 imprinted region. Consequently, we identified three patients with methylation defects in the GNAS-DMRs. Patients 1, 2, and 3 had 9, 5, and 4 points in a BWSp score, respectively. All three patients had macroglossia and postnatal overgrowth. Further analyses, methylation-specific multiple ligation-dependent probe amplification for multiple DMRs, array-based methylation analysis, exome sequencing, array comparative genome hybridization analysis, and microsatellite marker analysis showed 9p deletion in Patient 1 and paternal uniparental isodisomy of chromosome 20 in Patient 2 together with multiple methylation defects in DMRs other than the GNAS-DMRs. Patient 3 had methylation defects in only the GNAS-DMRs.
conclusionMethylation defects in the GNAS-DMRs can cause the BWS-phenotype. For cases with the BWS-phenotype but no molecular defects in the 11p15.5 imprinted region, methylation analysis for the DMRs at the GNAS locus should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.